PT-141
Symbol Pt · MW 1025 Da
Melanocortin agonist studied for sexual response and libido.
- Discovered
- 2000
- Half-life
- 3 hours
- Approval
- FDA-approved (Vyleesi)
Reported effects
- Libido support
- CNS-mediated
- Sexual function
Overview
PT-141, also known as Bremelanotide, is a melanocortin receptor agonist used for sexual desire and arousal-related support. Unlike medications that primarily affect blood flow, PT-141 works through central nervous system pathways involved in sexual response. It is commonly discussed for libido, sexual function, arousal, and hormone-related wellness. Bremelanotide is medically approved for specific cases of hypoactive sexual desire disorder in premenopausal women. Its purpose is to support sexual desire through melanocortin signaling rather than through testosterone replacement or vascular stimulation.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- 1.75 mg
- Typical Frequency
- As needed, at least 45 minutes before anticipated sexual activity; maximum once per 24 hours and no more than 8 doses per month
Research sources
Source links included from peer-reviewed literature and trusted medical journal records for this peptide.
Interested in PT-141?
Enter your email and we'll send you a curated list of vendors we trust for sourcing this peptide.
No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions.